Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label, Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 in the Perioperative Treatment of Locally Advanced Microsatellite Instability/Mismatch Repair Protein-Deficient Gastric and Colorectal Cancers

NCT04556253 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT04556253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04556253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label, Phase II Study of Anti-PD-1/CTLA-4 Bispecific Antibody AK104 in the Perioperative Treatment of Locally Advanced Microsatellite Instability/Mismatch Repair Protein-Deficient Gastric and Colorectal Cancers
Lead sponsor
Peking University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 28, 2024
Completion date
December 31, 2028
Enrollment
47 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

msi-h/dmmr gastric carcinoma and colorectal cancer